Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Cellerant Therapeutics Inc (AKA: Celtrans LLC)
Profile last edited on: 1/14/19      CAGE: 47BJ6      UEI: LML1YE6L8KU3

Business Identifier: Oroducts for regulation of hematopoietic system (blood-forming)
Year Founded
2000
First Award
2003
Latest Award
2019
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1561 Industrial Road
San Carlos, CA 94070
   (650) 232-2122
   info@cellerant.com
   www.cellerant.com
Location: Single
Congr. District: 14
County: San Mateo

Public Profile

Cellerant Therapeutics, formerly doing business as Celtrans LLC, is a clinical stage biotechnology company developeing a portfolio of products based on the regulation of hematopoietic (blood-forming) systems. The company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant is developing a novel, cell-based medicine (Myeloid Progenitors / CLT-008), as a treatment for chemotherapy- and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.

Extent of SBIR involvement

User Avatar
Phase I Awards
8
Phase II Awards
4
Conversion Rate
50.00%
Phase I Dollars
$2,226,936
Phase II Dollars
$3,851,053
Total Awarded
$6,077,989

Synopsis: Awardee Business Condition

Employee Range
75-99
Revenue Range
7.5M-10M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2019 2 NIH $1,317,946
Project Title: Novel Indication for Myeloid Progenitor Use: Induction of Tolerance
2014 1 NIH $223,524
Project Title: OTHER FUNCTION: Development of IL1RAP antibodies targeting AML CS
2012 1 NIH $194,467
Project Title: Development of a Process for Generating Human MKP
2008 1 NIH $500,000
Project Title: Development of Ex Vivo Expanded Megakaryocyte Progenitors for Platelet Recovery F
2008 2 NIH $594,835
Project Title: Attenuation of Radiation-Induced GI Injury by Cultured Myeloid Progenitors

Key People / Management

  Ram Mandalam -- President; Chief Executive Officer

  Elisa Brunette -- Director of Technology Transfer

  Julie L Christensen

  Bruce Cohen

  Margaret Dillon -- Senior Vice President, Regulatory Affairs, Quality Assurance & Project Managemen

  Jos Domen

  Timothy C Fong

  Jagath Juntula

  Holger Karsunky

  Swapna Panuganti

  William Reed -- Vice President, Clinical Development

  David C Scherer

  Robert Tressler -- Vice President of Research & Development

  Jun S Yoon -- Director of Corporate Development

  Jun S Yoon -- Vice President, Corporate Development

  Rodney Young -- Chief Financial Officer

  Deborah Zimmerman

Company News

Dec 05 2014
Cellerant to Present Phase 1 Clinical Data on Evaluation of CLT-008 in Patients with Acute Myeloid Leukemia At the 2014 American Society of Hematology Annual Meeting
Sep 04 2012
CELLERANT AWARDED $36.4 MILLION OPTION UNDER EXISTING U.S. GOVERNMENT CONTRACT TO SUPPORT DEVELOPMENT OF CLT-008 FOR TREATMENT OF ACUTE RADIATION SYNDROME
Sep 26 2011
Studies to continue in development of new way to treat blood damage from radiation
Cellerant Announces Dosing of First Patient in Randomized Phase 2 Clinical Trial of CLT-008 in Acute Myeloid Leukemia Patients